Safety and Efficacy Study of IMSA101 in Refractory Malignancies

• Status: Recruiting
• Trial end date: 2023-02-16
• Target enrollment: 0
• Participant gender: All

Summary

Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II)

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ImmuneSensor Therapeutics Inc.
• Treatments: Immune Checkpoint Inhibitors

Criteria

Inclusion Criteria:

1. Signed informed consent and mental capability to understand the informed consent

2. Male or female patients > 18 years of age

3. Histologically or cytologically documented locally advanced or metastatic solid tumor malignancies refractory to or otherwise ineligible for treatment with standard-of-care agents/regimens, including but not limited to:

• Malignant melanoma

• Hormone receptor negative breast cancer

• Gastro-esophageal cancer

• Non-small cell lung cancer

• Head and neck cancer

• Hepatoma

• Renal cell carcinoma

4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1

5. Evaluable or measurable disease as follows:

• A minimum of 3 RECIST-evaluable lesions: one that is suitable for injection and biopsied; one non-injected that will be biopsied for abscopal effect; and one measurable lesion that will be followed for response only.

• Injectable tumors shall be accessed by intralesional (cutaneous) or percutaneous injection only, including those lesions that are visible, palpable, or detectable by standard radiographic or ultrasound methods. Neither surgical procedures nor endoscopically-guided injections including those to endobronchial, endoluminal, or endosinusial spaces shall be allowed. While no anatomic locations are required or disallowed, lesions selected for intratumoral injection must, in the opinion of the investigator:

• Not be immediately adjacent to blood vasculature or other physiologic landmarks in such a way that will accrue undue safety risk to the patient

• Have longest diameter ≥ 10 mm and ≤ 50 mm

• Be fully efficacy evaluable per RECIST v1.1 criteria

6. Life expectancy > 3 months (Phase I) and > 6 months (Phase IIA)

7. ECG without evidence of clinically meaningful conduction abnormalities or active ischemia as determined by the investigator

8. Acceptable organ and marrow function as defined below:

• Absolute neutrophil count > 1,500 cells/μL

• Platelets > 50,000 cells/μL

• Total bilirubin ≤ 1.5 times the upper limit of normal (ULN)

• Aspartate aminotransferase (AST)/alanine transaminase (ALT) ≤ 2.5 times ULN. If liver metastases are present, AST/ALT < 5 times ULN

• Serum creatinine < 1.5 mg/dL and a measured creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula

• Prothrombin time (PT)/partial thromboplastin time (PTT) ≤ 1.5 times ULN

9. Women of child-bearing potential (defined as a female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months with an appropriate clinical profile at the appropriate age, e.g., greater than 45 years) must have a negative serum pregnancy test prior to first dose of study drug

10. Male and female patients with reproductive potential must agree to use two forms of highly effective contraception throughout the study

11. Phase I combination only: Demonstrated RECIST stable disease through ≥ 4 consecutive cycles of an approved PD-1 or PD-L1 targeted ICI with no Grade ≥ 3 CTCAE events considered by the investigator to be drug-related.

Exclusion Criteria:

1. Anti-cancer therapy within 4 weeks or < 5 half-lives of the first dose of study drug.

2. Failure to recover to Grade 1 or less from clinically significant AEs due to prior anti-cancer therapy.

3. Known untreated brain metastases or treated brain metastases that have not been stable (scan showing no worsening of central nervous system (CNS) lesion[s] and no requirement of corticosteroids) ≥ 4 weeks prior to study enrollment

4. Baseline prolongation of QT/QTc interval (QTc interval > 470)

5. Uncontrolled intercurrent illness (including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations) that in opinion of the investigator would limit compliance with study requirements

6. Women who are pregnant or breastfeeding

7. Phase I combination only: Prior tumor progression through PD-1 or PD-L1 targeted ICI therapy.